This week on the podcast Agustin discusses some new developments in the Alzheimer's space with the FDA's recent CRL for Eli Lilly's beta amyloid antibody. He also shares his thoughts on Leap Therapeutics' acquisition of Flame Biosciences and what it means for future commercialization strategies 

All Business. No Boundaries.
Welcome to All Business. No Boundaries, a collection of supply chain stories by DHL...

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com